First-line regimens with endocrine therapy show benefits in breast cancer
First-line regimens with endocrine therapy (ET) may be associated with benefits among patients with human epidermal growth factor receptor 2-positive (ERBB2-positive [formerly HER2-positive]) metastatic breast cancer (MBC), ...
Dec 20, 2022
0
0